| Patient | Marie Curie |
|---|---|
| Date of birth | 1867-11-07 |
| Identifiers | MRN HR-ET013-SYN-TD; SSN (made up) 000-13-2758 |
| Document date | 1934-06-08 |
| Author | Adaeze Nwosu, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-week review on immunosuppressive therapy, and glare in the right eye. [S]
Madame Curie returns three weeks after starting horse antithymocyte globulin, cyclosporine, eltrombopag, and acyclovir. She completed the four-day antithymocyte globulin course. She takes cyclosporine twice daily, eltrombopag on an empty stomach away from dairy, and acyclovir twice daily, and has missed no doses. She has had no fever, chills, sore mouth, rash, or joint pain, and no new bleeding beyond occasional bruises. She still tires by midafternoon and is writing at home on shortened days. Glare from the right eye makes small print and night driving difficult, and it is slowing her reading. [S]
| Element | Detail |
|---|---|
| Treatment | Antithymocyte globulin course completed; cyclosporine, eltrombopag, and acyclovir taken as prescribed |
| Infection | No fever, chills, or sore mouth |
| Bleeding | Occasional bruises; no mucosal bleeding |
| Function | Tired by midafternoon; writing at home on shortened days |
| Vision | Right-eye glare slowing her reading; night driving difficult |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue by midafternoon; no fever or chills |
| Hematologic | Positive | Occasional bruises; no mucosal bleeding |
| Eyes | Positive | Glare and blurred reading vision in the right eye; no pain or flashes |
| Skin | Negative | No rash |
| Musculoskeletal | Negative | No joint pain |
| Neurological | Negative | No tremor or headache |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cyclosporine (modified) 100 mg oral capsule, one capsule twice daily, dose adjusted to trough levels by hematology | One capsule by mouth twice daily; hematology adjusts the dose to trough levels | Oral route | 1934-05-18 | active | S |
| Eltrombopag 75 mg oral tablet, two tablets (150 mg) once daily on an empty stomach | Two tablets by mouth once daily, two hours before or four hours after food, dairy, or antacids | Oral route | 1934-05-18 | active | S |
| Acyclovir 400 mg oral tablet, one tablet twice daily during immunosuppression | One tablet by mouth twice daily | Oral route | 1934-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1934-06-08 | Body height | 157 | cm | S |
| 1934-06-08 | Body weight | 51.5 | kg | S |
| 1934-06-08 | Body mass index (BMI) [Ratio] | 20.9 | kg/m2 | S |
| 1934-06-08 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1934-06-08 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1934-06-08 | Heart rate | 90 | /min | S |
| 1934-06-08 | Respiratory rate | 16 | /min | S |
| 1934-06-08 | Body temperature | 36.8 | Cel | S |
| 1934-06-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1934-06-08 | Hemoglobin [Mass/volume] in Blood | 8.2 | g/dL | 11.6-15 g/dL | Low | S |
| 1934-06-08 | Leukocytes [#/volume] in Blood by Automated count | 2 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1934-06-08 | Neutrophils [#/volume] in Blood by Automated count | 0.5 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 1934-06-08 | Platelets [#/volume] in Blood by Automated count | 21 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1934-06-08 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 102 | fL | 80-100 fL | High | S |
| 1934-06-08 | Reticulocytes [#/volume] in Blood by Automated count | 18 | 10*3/uL | 25-100 10*3/uL | Low | S |
| 1934-06-08 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-35 U/L | Normal | S |
| 1934-06-08 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1934-06-08 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1934-06-08 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1934-06-08 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1929)/1.73 sq M | 65 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1934-06-08 | Glucose [Mass/volume] in Serum or Plasma | 101 | mg/dL | 70-99 mg/dL | High | S |
Vital signs recorded on 1934-06-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Pale but less tired-looking; alert |
| Mouth | No ulcers, thrush, or gum swelling |
| Skin | A few bruises on the shins; no petechiae or rash |
| Heart | Regular rhythm, pulse 90 |
| Eyes | Right red reflex hazy, with glare on penlight; left red reflex clear |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Severe aplastic anemia: pancytopenia with a low reticulocyte count, confirmed by a hypocellular bone marrow; attributed to cumulative occupational ionizing radiation; linked to the documented 1842 diagnosis | active | confirmed | D61.2 | S — Synthetic modern diagnosis; the 1934 report remains D and the radiation cause is R. |
| Occupational exposure to ionizing radiation over decades of radium research and X-ray work | active | confirmed | Z57.1 | S — Synthetic modern coding of the documented exposure history. |
| Posterior capsule opacification, right eye, after earlier bilateral cataract surgery; glare and blurred reading vision | active | confirmed | H26.491 | S — Synthetic eye finding linked to the documented cataracts and operations. |
| Chronic radiodermatitis of the fingertips, with thin, scarred skin | active | confirmed | L58.1 | S — Synthetic skin finding linked to the documented finger burns. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | CBC with differential and reticulocyte count | Weekly during the first months of treatment | Completed today | Hemoglobin 8.2 g/dL, white cells 2.0, neutrophils 0.5, platelets 21, reticulocytes 18 thousand per microliter |
| Laboratory | Weekly blood counts between visits | Weekly during the first months of treatment | Deferred | No counts are in this record between the consultation and today, so two weekly counts were missed, a deviation from the protocol. Platelets stayed above 15 and there was no bleeding or fever, so no harm resulted. Corrective action: weekly counts booked with the hematology day unit |
| Laboratory | Creatinine, eGFR, potassium, and ALT on cyclosporine and eltrombopag | Every two weeks during the first months of treatment | Completed today | First check, three weeks after starting, a week later than the two-week schedule. Creatinine 0.96 mg/dL (up from 0.78), eGFR 65, potassium 4.8, ALT 28, sodium 138; glucose 101 mg/dL, slightly high |
| Laboratory | Cyclosporine trough level | Regularly from the first weeks of treatment, to guide the dose | Deferred | No trough level is in this record since cyclosporine started, a deviation from the protocol. The creatinine rise may reflect cyclosporine effect. Corrective action: trough requested from hematology with the next counts |
| Laboratory | Viral serology before immunosuppression (hepatitis B, hepatitis C, HIV, CMV, EBV) | At diagnosis, before immunosuppression | Deferred | Still not in this record; not sent with today's blood, a second miss. ALT is normal, with no sign of hepatitis. Corrective action: results requested from hematology |
| Examination | Blood pressure and weight on cyclosporine | Every visit | Completed today | 124/76 mmHg, up from 116/70 before cyclosporine; weight 51.5 kg |
| Medication safety | Antiviral prophylaxis during immunosuppression | Throughout immunosuppression | Completed today | Taking acyclovir twice daily |
| Medication safety | Antibacterial and antifungal prophylaxis while severely neutropenic | While neutrophils are below 0.5 thousand per microliter, by local policy | Deferred | Still not prescribed; neutrophils 0.5, at the threshold, with no infection. Hematology to confirm under local policy |
| Medication safety | Eltrombopag administration | Every visit | Completed today | Taken on an empty stomach, away from dairy and antacids |
| Self-management | Same-day assessment for a temperature of 38 °C or higher; bleeding precautions; no aspirin or NSAIDs | Every visit | Completed today | No fever; plan reviewed |
| Survey | Symptom assessment (fatigue, breathlessness, exercise tolerance) | Every visit during active treatment | Completed today | Tired by midafternoon; breathless after one flight of stairs |
| Survey | Functional vision assessment (reading, driving, work) | When symptoms limit daily tasks | Completed today | Glare limits small print, reading, and night driving |
| Referral | Comprehensive dilated eye examination | Every 1 to 2 years at 65 or older, and with new functional impairment | Referred | Ophthalmology appointment next week |
| Survey | Response assessment (blood counts off transfusion) | At three and six months | Due | Formal response is judged at three months |
| Survey | Depression screen (PHQ-2) | Periodically during serious illness | Due | Score 1 at intake; repeat at the next visit |
Goal progress:
Guideline basis: Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline (2024); Cataract in the Adult Eye Preferred Practice Pattern (2021); CMID: Clinical Monitoring Intelligence Database, anemia and cataract monographs (2026)
Follow-up: Weekly blood counts. Ophthalmology next week. Primary care review in three weeks with blood counts, kidney function, potassium, and ALT. Next scheduled visit 1934-06-29: primary care follow-up six weeks into immunosuppressive therapy, after laser capsulotomy of the right eye. [S]